Acacia Diversified Holdings Inc (OTCMKTS: ACCA) is making a strong move up the charts since reversing off double zero lows. The stock has transformed into a volume leader and has quickly attracted a fast growing shareholder base.
The Company has an exciting portfolio including Eufloria Medical of TN, Inc., a vertically integrated bioscience company producing all-natural, sustainably farmed hemp in Tennessee. Eufloria is an environmentally and socially responsible company developing phytocannabinoid & terpene rich broad spectrum, strain-specific profiles through our genetic development and cultivation methodology.
Acacia Diversified Holdings Inc (OTCMKTS: ACCA) has a wholly-owned subsidiary for growing hemp called Eufloria and it uses its processing and manufacturing company, MariJ to create consumer products for distribution under the Eufloria brand. Dahlia’s Botanicals is another part of the Acacia portfolio, with a portion of sales from its U.S.D.A Certified Organic Hemp product going to the Canna-moms 501(3)c organization.
In January 2016 the Company acquired the MariJ Group of companies in Clearwater, Florida, and integrated those acquired assets into two new subsidiaries of Acacia: MariJ Pharmaceuticals, Inc. and Euflorida Medical of TN. Inc., giving the Company a very strong posture in this young, explosive-growth industry with state-of-the-art technology and equipment and a highly-knowledgeable, skilled and energetic management team.
To Find out the inside Scoop on ACCA Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Utilizing its unique mobile high-quality, high-yield medical cannabis oil extraction technologies and our blending, processing, compounding and packaging technologies combined with vertically intergraded hemp farm with certification technologies, the Company is poised to grow quickly in both wholesale and retailing operations. MariJ Pharma specializes in using the highest-quality, certified organic hemp for its ingredients and received its Organic Certification from OneCert, Inc. under the U.S National Organic Program (7 CFR Part 205) for its proprietary CO2 mobile cannabis oil extraction process and handling. The Company will also seek to become engaged as a licensed grower or hemp buyer in other states for hemp production in 2019 and is also preparing to rollout its proprietary HIPAA compliant GeoTraking “Seed to Patient” software with related RFID “Soil to Oil” plant tracking technology for the medical profession.
In January ACCA reported it has received its final Patent #10561693 for the Company’s Cultivation, Processing and Synthesis of Cannabidiols on products made with patented CO2 technology as a full spectrum, whole plant hemp product. Included in the Patent are tinctures, capsules, distillate and isolate along with the Company’s USDA certified organic Dahlia’s Botanicals product and 1,200mg hemp oil sublingual grown by Eufloria and processed and manufactured by cGMP certified MariJ.
These products were highly recognized in the Southern Championship Cup that was held in Nashville, Tennessee on December 8, 2019. In the Consumables category, Dahlia’s Botanicals was awarded 1st place and Eufloria’s 1,200mg had the honor of 2nd place in the competition. The Company believes that the awarded patent will be a huge benefit going forward as the hemp industry evolves. These products will be debuting on Amazon for customers to purchase.
“We are pleased, for our shareholders, processing and manufacturing a product line that is full spectrum, whole plant hemp oil with zero residual solvents and no contaminates with our now patented CO2 technology,” said Richard K. Pertile, Acacia’s Chief Executive Officer.
On May 14 ACCA filed an NT 10K stating – The Registrant has been experiencing cash flows issues that are exacerbated by the recent COVID-19 pandemic. Therefore, Registrant has not had sufficient cash flows to hire its current independent registered public accounting firm to complete an audit of our financial statements for the year ended December 31, 2019. Registrant is relying on Securities and Exchange Commission (the “Commission”) Release No. 34-88465 dated March 25, 2020 and the Commission Order contained therein in connection with filing this Form 12b-25.
We have a Monster Pick Coming. Subscribe Right Now!
Currently on the move ACCA has a clean balance sheet, with manageable debt and some revenues reporting $400k in sales for the 9 months ended September 30, 2019. ACCA is making a strong move up the charts in recent days quickly attracting a fast growing shareholder base. In a big move in January ACCA reported it has received its final Patent #10561693 for the Company’s Cultivation, Processing and Synthesis of Cannabidiols on products made with patented CO2 technology as a full spectrum, whole plant hemp product. Included in the Patent are tinctures, capsules, distillate and isolate along with the Company’s USDA certified organic Dahlia’s Botanicals product and 1,200mg hemp oil sublingual grown by Eufloria and processed and manufactured by cGMP certified MariJ. We will be updating on ACCA on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with ACCA.